Investor Relations
About Vivani
Vivani Medical is an emerging biopharmaceutical company developing a pipeline of miniature, long-term drug implants with its proprietary NanoPortal™ platform technology for obesity/weight management and other chronic diseases.
Vivani’s lead drug implant candidates are designed to improve medication adherence and deliver smooth consistent therapeutic levels of GLP-1 – the same class of active pharmaceutical ingredients in Ozempic®, Trulicity® and Wegovy® – for six months or longer with a single administration. NPM-115 and NPM-119, are miniature, six-month, GLP-1 (exenatide) implants under development for obesity/chronic weight management and the treatment of type 2 diabetes, respectively.
As a result of positive preclinical weight loss data comparing NPM-115 to Ozempic/Wegovy and the transformational change in the obesity market, Vivani has decided to prioritize development of its obesity portfolio moving forward which also includes NPM-139 (semaglutide implant) with the potential for once-yearly dosing.
Vivani continues to proceed towards initiating LIBERATE-1, a First-in-Human (FIH) study assessing the exenatide implant’s safety and pharmacokinetic profile in obese and overweight individuals. In addition to an active control arm with Bydureon BCise®, LIBERATE-1 will also include a second active control arm with Wegovy (semaglutide injection).
NanoPortal™ has broad potential application across a range of molecule types including peptide therapeutics.